Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
Shun Lü(Shanghai Jiao Tong University), Lin Wu(Central South University), Hong Jian(Shanghai Jiao Tong University), Ying Chen(Jilin Province Tumor Hospital), Qiming Wang(Henan Cancer Hospital), Jian Fang(Peking University), Ziping Wang(Peking University), Yanping Hu(Hubei Cancer Hospital), Meili Sun(Shandong University), Liang Han(Xuzhou Central Hospital), Liyun Miao(Nanjing Drum Tower Hospital), Cuimin Ding(Hebei Medical University), Jiuwei Cui(Jilin University), Baolan Li(Capital Medical University), Yueyin Pan(Anhui Provincial Hospital), Xingya Li(First Affiliated Hospital of Zhengzhou University), Feng Ye(First Affiliated Hospital of Xiamen University), Anwen Liu(Nanchang University), Ke Wang(Sichuan University), Shundong Cang(Henan Provincial People's Hospital), Hui Zhou, Xing Sun, David Ferry(Eli Lilly (United States)), Yong Lin(Eli Lilly (United States)), Shuyan Wang, Wen Zhang, Chengli Zhang
Cited by 238
Abstract
Related Papers
No related papers found
Powered by citation graph analysis